Being a careful person, I found that there are some hidden passwords in the clues of the market. Let's tell you why the share price of Kangxinuo Bio has soared.
On August 16th, Kangxinuo Bio officially disclosed that China National Intellectual Property Administration recently published a document, and the COVID-19 vaccine (Ad5-nCoV) jointly developed by Kangxinuo Bio and Academician Chen Wei was awarded the invention patent right. This is the first COVID-19 vaccine patent in China.
today, the market opened, and Kangxinuo Bio went all the way up. As of 12 noon, the Hong Kong stock market rose more than 14%, with the highest share price of HK$ 232 and a market value of over HK$ 54 billion. The share price of the science and technology innovation sector rose by more than 7%, and its market value exceeded 92 billion yuan. In a short period of half a day, the market value of Hong Kong stocks soared by HK$ 6.6 billion, while the market value of A shares also rose by RMB 5.6 billion.
Four days ago, Kangxinuo Bio-Co., Ltd. just boarded the scientific and technological innovation section and became the first "a+H" vaccine stock. The stock opened up 124% that day, and its market value once exceeded RMB 1 billion. In March 219, Kangxinuo Bio was listed on the Hong Kong Stock Exchange. At that time, the opening price was only HK$ 3.5. In the blink of an eye, it rose to the highest point of 285.8 Hong Kong dollars in more than a year, with an increase rate of more than 1 times.
after more than ten years' business, Kangxinuo Bio can't do without the firm running of many first-line VCs/PEs behind it, such as Lilly Asia Fund, Qiming Venture Capital, SDIC Innovation, CITIC Securities, Dachen Venture Capital and Gefei Assets. This time, a number of investors told the investment community the story behind the original bet on Kangxinuo Bio. They believe that they are investing in a star enterprise that may stir up the vaccine pattern in China and even the world in the future.
after ten years of research and development, Kangxinuo Bio has not yet commercialized its products. According to the prospectus, from 216 to 218, Kangxinuo Bio lost 49.9 million yuan, 64.5 million yuan and 138 million yuan respectively. In March of this year, Kangxinuo Bio released its first annual report after IPO. In 219, the company did not realize revenue, with a net loss of 157 million yuan.
just four days ago, on August 13th, Connaught Bio-Co., Ltd. just boarded the scientific and technological innovation section and became the first "a+H" vaccine stock. On the same day, the stock rose by 124%, and its market value once exceeded RMB 1 billion. Today, Kangxinuo Bio-Co., Ltd. rose more than 7% at the opening, and its share price reached 38 yuan, with a market value of over 92 billion yuan. In just half a day, the market value of A shares rose by 5.6 billion yuan.
Back one year ago, in March 219, Concordia Bio was listed on the Hong Kong Stock Exchange. At that time, the opening price was only HK$ 3.5, reaching the highest point of HK$ 285.8 in more than a year, an increase of more than 1 times. As of midday today, the Hong Kong stock market rose by more than 14%, with the highest share price of HK$ 232 and a market value of over HK$ 54 billion. The value of the stock market soared by HK$ 6.6 billion in half a day.
Many investors told the investment community that they would still support Connaught Bio after its listing. Because compared with the listing itself, its product line has unlimited significance and value. China really needs a reliable world-class vaccine giant.